2-噁唑甲腈 | 68776-60-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-噁唑甲腈
• 中文别名: 2-氰基噁唑
• 英文名称: 2-cyanooxazole
• 英文别名: Oxazole-2-carbonitrile；1,3-oxazole-2-carbonitrile
• CAS: 68776-60-3
• 化学式: C₄H₂N₂O
• mdl: MFCD08669511
• 分子量: 94.0727
• InChiKey: UUAXDPHPSHEGQQ-UHFFFAOYSA-N

物化性质

• 沸点：
  165.7±23.0 °C(Predicted)
• 密度：
  1.25±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 储存条件：
  温度：2-8°C，保存条件：惰性气体

反应信息

• 作为反应物：
  描述：

  2-噁唑甲腈 在 sodium methylate 、 氯化铵 作用下， 以 甲醇 为溶剂， 反应 3.0h， 生成 oxazole-2-carboximidamide hydrochloride
  参考文献：
  名称：

  Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors

  摘要：

  Described herein are the discovery and structure activity relationship (SAR) studies of the third-generation 4-H heteroaryldihydropyrimidines (4-H HAPs) featuring the introduction of a C6 carboxyl group as novel HBV capsid inhibitors. This new series of 4-H HAPs showed improved anti-HBV activity and better drug-like properties compared to the first- and second-generation 4-H HAPs. X-ray crystallographic study of.analogue 12 (HAP_iR01) with Cp149 Y132A mutant hexamer clearly elucidated the role of C6 carboxyl group played for the increased binding affinity, which formed strong hydrogen' onding interactions with capsid protein and coordinated waters. The representative analogue 10 (HAP_R10) was extensively characterized in vitro (ADMET) and in vivo (mouse PK and PD) and subsequently selected for further devehipffientas oral anti-HBV infection agent.

  DOI：

  10.1021/acs.jmedchem.7b00083
• 作为产物：
  描述：

  2-噁唑羧酰胺 在 吡啶 、 三氯氧磷 作用下， 反应 4.0h， 生成 2-噁唑甲腈
  参考文献：
  名称：

  [EN] HETEROCYCLYL AND CYCLOALKYL SUBSTITUTED THIENO [2,3-D] PYRIMIDINE AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS
  [FR] THIÉNO[2,3-D]PYRIMIDINE À SUBSTITUTION HÉTÉROARYLE ET CYCLOALKYLE ET SON UTILISATION COMME ANTAGONISTE DES RÉCEPTEURS DE L'ADÉNOSINE A2A

  摘要：

  本发明涉及一种新型噻吩[2,3-d]嘧啶Z及其治疗和预防用途，其中X，R1和R2在说明书中有定义。治疗和/或预防的疾病包括帕金森病。公式（I）。

  公开号：

  WO2010045016A1

文献信息

• 7-AZAINDOLE INHIBITORS OF CRAC
  申请人：Hoffmann-La Roche Inc.

  公开号：US20130158049A1

  公开（公告）日：2013-06-20

  Disclosed are compounds of Formula (I): useful for treatment of autoimmune and inflammatory diseases associated with IL-2 inhibition via modulation of calcium release-activated calcium (CRAC) channels. Also disclosed are methods of making and using the compounds for treatment of diseases associated with CRAC channels.

  公开了公式(I)的化合物： 用于治疗与IL-2抑制有关的自身免疫和炎症性疾病，通过调节钙释放激活钙(CRAC)通道。还公开了制造和使用这些化合物用于治疗与CRAC通道相关的疾病的方法。
• Azaphilic versus Carbophilic Coupling at CN Bonds: Key Steps in Titanium-Assisted Multicomponent Reactions
  作者：Torsten Roth、Hubert Wadepohl、Eric Clot、Lutz H. Gade

  DOI：10.1002/chem.201503732

  日期：2015.12.14

  mediated by titanium(IV) alkoxides. The carbo‐ and azaphilic arylation step may be separated by choosing the order in which the two equivalents of aryl transfer reagent are added. In the course of this transformation, the ancillary N‐heterocycle acts as both a directing anchor group and electron reservoir. In the selectivity‐determining step, the selectivity is governed by a choice between (direct) C‐ and

  N-杂环腈的连续C-和N-芳基化是由钛(IV)醇盐介导的。碳芳基化步骤和氮亲芳基化步骤可以通过选择添加两当量芳基转移试剂的顺序来分开。在这个转变过程中，辅助的N-杂环既充当导向锚基团又充当电子库。在选择性确定步骤中，选择性由（直接）C-芳基化和Ti-芳基化之间的选择决定；后者开辟了一条反应途径，允许进一步迁移到氮原子。从反应混合物中分离含金属聚集体和计算研究为反应机理提供了见解。随后，设计了一种多组分一锅法方案来快速访问复杂的季碳中心。
• INDOLE DERIVATIVES AS CRAC MODULATORS
  申请人：Alam Muzaffar

  公开号：US20110071150A1

  公开（公告）日：2011-03-24

  Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 and R 4 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with calcium release-activated calcium channels (CRAC).

  公式I的化合物： 或其药用可接受的盐， 其中R1、R2、R3和R4按本文定义。还公开了制造这些化合物的方法以及使用这些化合物治疗与钙释放激活钙通道（CRAC）相关疾病的用途。
• DIAZAINDOLE INHIBITORS OF CRAC
  申请人：Hoffmann-La Roche Inc.

  公开号：US20130158040A1

  公开（公告）日：2013-06-20

  Disclosed are compounds of Formula (I): useful for treatment of autoimmune and inflammatory diseases associated with IL-2 inhibition via modulation of calcium release-activated calcium (CRAC) channels. Also disclosed are methods of making and using the compounds for treatment of diseases associated with CRAC channels.

  公开了公式(I)的化合物： 用于治疗与IL-2抑制有关的自身免疫和炎症性疾病，通过调节钙释放激活钙(CRAC)通道。还公开了制造和使用这些化合物用于治疗与CRAC通道相关的疾病的方法。
• 4-AZAINDOLE INHIBITORS OF CRAC
  申请人：Hoffmann-La Roche Inc.

  公开号：US20130158066A1

  公开（公告）日：2013-06-20

  Disclosed are compounds of Formula (I): useful for treatment of autoimmune and inflammatory diseases associated with IL-2 inhibition via modulation of calcium release-activated calcium (CRAC) channels. Also disclosed are methods of making and using the compounds for treatment of diseases associated with CRAC channels.

  公开了公式(I)的化合物： 用于治疗与IL-2抑制有关的自身免疫和炎症性疾病，通过调节钙释放激活钙(CRAC)通道。还公开了制造和使用这些化合物用于治疗与CRAC通道相关的疾病的方法。